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The Role of Metabolism in
the Estrogenic Activity of
Endocrine-Disrupting Chemicals
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Abstract
Exposure to several natural and synthetic chemicals can disrupt the endocrine
system and thus present a threat to human health. In vivo, such chemicals can be
metabolized, which can change the endocrine activity of the parent chemical.
Metabolism is usually considered to be a detoxification process, as it generally
appears to reduce the estrogenic activity of a chemical and accelerate its elimination
from the body. This is seen for bisphenol A (BPA), a known agonist of the estrogen
receptor, whereby BPA glucuronide has no effects on this receptor. In contrast,
numerous metabolites that show significantly greater estrogenic activities from
their parent chemicals have been described in the literature. An example is the ipso
metabolite of BPA, 4-methyl-2,4-bis(p-hydroxyphenyl)pent-1-ene, which shows
>100-fold estrogenic activity compared to BPA. Consideration of metabolic path-
ways in in vitro models is therefore of great importance for reliable analysis and
correct in vitro to in vivo correlations. The inclusion of metabolic aspects in these
assays will reduce false-positive data for chemicals that are detoxified in vivo and
false-negative data for proestrogens. Different approaches for this incorporation of
metabolic systems for determination of estrogenic activities are already in use and
are described in the present chapter.
Keywords: endocrine-disrupting chemicals, metabolic bioactivation, bisphenols,
estrogenic activity, in vitro assays
1. Introduction
According to the World Health Organization definition from 2002, an
endocrine-disrupting chemical (EDC) is an exogenous substance, or a mixture of
substances, that alters the function(s) of the endocrine system and consequently
that causes adverse health effects in the intact organism or its progeny or in (sub)
populations [1]. The occurrence of EDCs in the environment is widespread, and
exposure to EDCs is connected with many modern illnesses, such as cancers and
metabolic syndrome [2, 3]. Effects of some EDCs on nuclear receptors have been
reported even at very low doses, and thus EDCs have promoted increased concern
among scientists and regulators [4–6]. As a result, over the last two decades,
numerous in vitro and in vivo assays have been developed for the identification of
EDCs [7, 8]. In vitro assays represent an important step, especially in the early stages
of testing, as they can provide valuable information about the mechanisms of
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endocrine disruption (e.g., binding to the estrogen receptor [ER]). The main draw-
back of commonly used in vitro systems for estrogenic activity is that they do not
consider pharmacokinetic parameters and especially the metabolism of a tested
chemical [9].
Metabolism is the enzymatic process by which lipophilic compounds are
transformed into hydrophilic metabolites, which can then be rapidly excreted with
the urine. The liver is the main site of drug metabolism, although metabolic reactions
also occur in extrahepatic tissues, like the gut and the airways [10]. Phase I metabolic
reactions mainly consist of oxidation, reduction, and hydrolysis. During phase I
metabolism, new polar functional groups, like hydroxyl or carboxyl groups, are
introduced into the parent molecules, which results in either excretion of the modi-
fied chemical with the urine or in further metabolism by phase II metabolic reactions.
During phase II metabolism (i.e., conjugation reactions), chemicals are conjugated
with endogenous hydrophilic molecules (e.g., glucuronic acid, sulfate, glycine, and
acetyl group), which strongly increases their hydrophilicity and facilitates their
excretion. Metabolism can also influence the biological activity of a chemical. In most
cases, metabolism works as a detoxification system, as it can convert biologically
active chemicals into less active or even inactive metabolites [11]. In contrast, some
chemicals that have no initial biological activity can be metabolically activated to a
biologically active chemical (i.e., prodrugs) [12]. The principle of prodrugs is often
used in the pharmaceutical industry, with the aim being to improve the pharmacoki-
netics of drugs [13]. For example, enalapril is a medication that is used for the
treatment of arterial hypertension, and in the body, it is metabolized by esterases to
the pharmacologically active compound enalaprilat [14]. Additionally, some
chemicals can be metabolized to reactive metabolites, as seen for the thiophene
moiety [12], and can have detrimental effects.
Thus, metabolism can strongly influence the endocrine activities of many
chemicals. Rybacka and coworkers developed an in silico model for the prediction
of endocrine-disrupting potential of industrial chemicals and their metabolites [15].
More than 6000 industrial chemicals were evaluated using this model, and 9% of
them were predicted to be positive for interactions with the ER. However, when
metabolism was incorporated into this model, this doubled the number of chemicals
that were defined as positive for interactions with the ER [15]. Metabolism can, for
example, significantly affect antiestrogenic and antiandrogenic activities of the new
Figure 1.
Metabolism of the new brominated flame retardants TBB and TBPH to their TBBA and TBMEPH metabolites
that show antiestrogenic and antiandrogenic activities, as determined using a yeast assay [16]. ER, estrogen
receptor; AR, androgen receptor.
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brominated flame retardants 2-ethylhexyl 2,3,4,5-tetrabromobenzoate (TBB) and
bis(2-ethylhexyl) tetrabromophthalate (TBPH). While these parent chemicals show
no activity toward ERs and androgen receptors, their metabolites 2,3,4,5-tetrabro-
mobenzoic acid (TBBA) and 2-ethylhexyltetrabromobenzoate ester (TBMEPH)
show antiestrogenic and antiandrogenic activities with IC50 values in the low
micromolar (Figure 1) [16].
However, as in vitro assays do not generally consider metabolic transformations
of chemicals, it can be difficult to detect chemicals without estrogenic activities that
are converted to metabolites with estrogenic activities (i.e., proestrogens). More-
over, in vitro estrogenic activities can be overestimated for compounds that are
metabolized to inactive metabolites in vivo [17]. This can result in poor in vitro to
in vivo predictions, as observed with benzyl-butyl phthalate, which has estrogenic
activity in the T47D-KBluc in vitro assay, but not in the in vivo uterotrophic assay.
This can be explained by the rapid hydrolysis of benzyl-butyl phthalate to its
monoester in vivo, which has no estrogenic activity [9]. In contrast, methoxychlor
metabolites have higher estrogenic activity than methoxychlor itself, which is why
the in vivo estrogenic activity for methoxychlor is higher than that predicted from
in vitro assays (Figure 2) [9].
Figure 2.
Metabolism of proestrogens to active metabolites with estrogenic activity. In all of these examples, hydroxylation
at the para position of the aromatic ring is responsible for the estrogenic activity.
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2. Metabolism of 17β-estradiol
17β-Estradiol (E2) metabolism has been extensively studied, especially in con-
nection with risk of premenopausal breast cancer [18, 19]. E2 can undergo aromatic
hydroxylation that is catalyzed by cytochromes P450, for the C2 and C4 positions of
the steroid rings, to form catechol structures, or for the C16 position of the steroid
rings, to form 16-hydroxyestrone structures [20]. Estrogen metabolites with a cat-
echol structure are further metabolized by catechol-O-methyltransferase to their
methylated metabolites, as shown in Figure 3. The 16-hydroxyestrones are further
metabolized to 17-epiestriols and estriols (Figure 3). As determined in the urine of
premenopausal women, in vivo the 16-hydroxylation pathway of estradiol metabo-
lism is the most important, followed by the 2-hydroxylation pathway, while the
4-hydroxylation pathway represents only minor metabolic conversion [20].
Different environmental factors and polymorphic variations in the genes that
encode metabolic enzymes have also been reported to affect estradiol metabolism
[24]. Smoking and high physical activity, for example, both favor the 2-hydroxyl-
ation metabolic pathway, with the 16-hydroxylation pathway decreased [25, 26].
Moreover, Gu and coworkers reported on connections between smoking and
increased metabolism of estradiol, increased activity of the 4-hydroxylation
metabolic pathway, and decreased methylation of estrogen metabolites [25].
The catechol estrogens 2-hydroxyestradiol and 4-hydroxyestradiol can bind to
the ER of MCF-7 cells, and their relative binding activities compared to E2 were
reported to be 23 and 26%, respectively [27]. These work as agonists of ER-
dependent gene expression in the MCF-7 cell line [28].
The estrogenic activities of E2 and its metabolites were evaluated in luciferase
reporter gene assays using T47D breast cancer cells (i.e., the ER-CALUX
assay) [21]. The estrogenic activities of the E2 metabolites were compared with that
of E2, which can be represented as the “E2 equivalency factor” (EEF) (Figure 3).
E2 was the most potent compound, while its metabolites had reduced estrogenic
Figure 3.
Endogenous metabolism of E2 together with the E2 equivalency factors (EEF) for the various metabolites, as
determined with the ER-CALUX assay [20–23]. COMT, catechol-O-methyltransferase.
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activities. Here, the 4-hydroxy metabolites, and especially 4-hydroxyestradiol,
had higher estrogenic activities than the 2-hydroxy metabolites [21]. Both of these
forms of hydroxylated estradiols (i.e., 4-hydroxyestradiol, 2-hydroxyestradiol)
increased uterine weight of neonatal rats, which confirmed their estrogenic activi-
ties in vivo [29]. 4-Hydroxyestradiol had greater in vivo estrogenic activity than
2-hydroxyestradiol (203, 107% increases in uterine weight, respectively) [29].
3. Impact of metabolism on estrogenic activity
As mentioned above, metabolites with altered estrogenic activity can be formed
during metabolism. In some cases, estrogenic activities can be predicted from the
structures of the metabolites. Some structural characteristics of the molecule are
known to be important for binding to the ER, such as the aromatic ring with an OH
group at the para position [30]. Hydroxylation of the para position of the aromatic
ring, which is a common phase I metabolic reaction, often enhances estrogenicity.
In contrast, glucuronides are devoid of estrogenic activity.
3.1 Metabolic activation of proestrogens
A number of chemicals that have been reported to be without estrogenic activ-
ities in vitro can affect the estrogen system in vivo. Methoxychlor is a broad-
spectrum pesticide, and as such it is one of the most studied proestrogens. While
methoxychlor has no estrogenic activity, its mono-demethylated and
bis-demethylated metabolites have significant estrogenic activities [31]. Mollergues
et al. determined the estrogenic activity of methoxychlor using the ER-CALUX
assay with and without the β-naphthoflavone-/phenobarbital-induced S9 fraction
[32]. In this assay, methoxychlor showed weak estrogenic activity (EC50 4.6 μM).
This estrogenic activity was significantly increased when the activated S9 fraction
was added to the assay (EC50 0.15 μM), which suggested the formation of active
metabolites of methoxychlor. The pure methoxychlor metabolite 4,40-(2,2,2-
trichloroethane-1,1-diyl) diphenol was also tested, and its estrogenic activity was
comparable with that of methoxychlor treated with the S9 fraction (EC50 0.05 μM),
which suggested that 4,40-(2,2,2-trichloroethane-1,1-diyl) diphenol is the main
metabolite formed with the S9 fraction [32]. As the methoxychlor metabolites
mono-OH methoxychlor and bis-OH-methoxychlor are formed both in vitro and
in vivo, addition of the metabolic enzymes here (i.e., the S9 fraction) improved the
in vivo prediction [33]. Additionally, Sumida and coworkers added a source of
metabolic enzymes (i.e., human and rat S9 and liver microsomes) to MCF-7 and
Hela reporter gene assays to determine the influence of metabolism on the estro-
genic activity of trans-stilbene and methoxychlor [33]. While these parent com-
pounds were without estrogenic activities, the addition of the metabolic enzymes
resulted in significant increases in estrogenicity [33].
Chalcone is an α,β-unsaturated ketone, and it is a structural fragment in many
natural chemicals. Chalcone itself is without estrogenic activity. However, estro-
genic activities were shown for its hydroxylated metabolites using a luciferase
reporter assay with the MCF-7 cell line (Figure 2) [34]. Similarly, CYP-mediated
hydroxylation on the aromatic ring of 4-phenyl-3-buten-2-ol results in estrogenic
activity of its 4-hydroxyl metabolite (Figure 2) [34]. Benzophenone-3 is a widely
used UV filter in sunscreens. While the estrogenic activity of benzophenone-3
determined with a reporter assay using CHO cells was weak, its main metabolite
2,4-dihydroxybenzophenone showed >20-fold ERα agonist activity (EC50 2.2,
0.099 μM, respectively) and 100-fold ERβ agonist activity (EC50 3.3, 0.033 μM,
5
The Role of Metabolism in the Estrogenic Activity of Endocrine-Disrupting Chemicals
DOI: http://dx.doi.org/10.5772/intechopen.81918
respectively) (Figure 2) [35]. This enhanced estrogenicity is, however, not surpris-
ing, as a 4-hydroxyl group on the phenol ring is essential for strong estrogenic
activity.
Permethrin and bifenthrin are pyrethroid pesticides [36]. In in vitro reporter gene
assays using the BG-1 cell line (i.e., CALUX bioassays), neither of them showed ER
agonist activity, while bifenthrin acted as an ER antagonist. However, both of these
pesticides induced expression of chloriogenin (i.e., an E2-responsive protein) in
in vivo assays in the juvenile fishMenidia beryllina, which indicated estrogenic activ-
ities for both of the parent pesticides or their metabolites in vivo [36].
These differences between the in vitro and in vivo data for permethrin might be due to
the formation of metabolites with higher estrogenic activities [37, 38]. Similarly, a
higher estrogenic activity of the parent bifenthrin that was shown in an in vivo study
was also seen for the bifenthrin metabolites [39].
3.2 Metabolic inactivation
Inconsistencies in the estrogenic activities obtained in vitro and in vivo were
also seen for different phthalates [40]. Here, the tested phthalates (i.e., n-butyl
benzyl phthalate, dicyclohexyl phthalate, 2-ethylhexyl phthalate, di-n-butyl
phthalate) showed estrogenic activities in an in vitroMCF-7 proliferation assay (i.e.,
the E-screen assay), but they did not induce expression of calbindin-D9K mRNA
in vivo in neonatal rat uterus [40]. The explanation here might lie in the rapid in vivo
metabolism of phthalates to monoester metabolites, which have no estrogenic
activity [41]. n-Butyl benzyl phthalate is rapidly metabolized to mono-n-butyl
phthalate, mono-benzyl phthalate, hippuric acid, phthalic acid, and benzoic acid
[42]. In two in vitro assays (i.e., E-screen assay, progesterone receptor assay on
MCF-7 cell line), n-butyl benzyl phthalate showed estrogenic activities, while its
metabolites were without activity (Figure 4) [42].
Loss of estrogenic activity has also been described for various glucuronides. For
example, the soy isoflavones genistein and daidzein are known as estrogens [43]. In
contrast, their glucuronides are not estrogenic [44]. Despite this, glucuronides have
shown very low estrogenic activities in in vitro reporter gene assays using U2OS cells
(0.002–0.0005-fold that of their aglycones), which can be explained by their
intracellular deconjugation to their corresponding aglycones [44]. Beekmann and
Figure 4.
Metabolism of the estrogenic compounds n-butyl benzyl phthalate to its inactive monoester metabolites (a) and
genistein to the inactive genistein glucuronide (b).
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coworkers used a cell-free microarray assay for real-time co-regulator-nuclear
receptor interactions, which enabled the detection of estrogenicity as an
agonistic response to the ER ligand-binding domain (LBD) [45]. They reported
0.125-fold to 0.00022-fold potencies for the glucuronides in comparison with
their corresponding aglycones for the modulation of ERα-LBD and ERβ-LBD-co-
regulator interactions [45].
Similarly, in vitro estrogenic activities were shown for p-nonylphenol and p-
octylphenol with yeast cells, with EC50 values in the high nanomolar range (EC50
110, 700 nM, respectively) [46]. Their glucuronides were without agonistic and
antagonistic estrogenic and androgenic activities [46]. Due to the rapid
glucuronidation of p-nonylphenol and p-octylphenol in vivo, these in vitro
estrogenicities probably do not reflect any hazards in vivo [46].
4. Bisphenols
The bisphenols are chemicals that contain two phenol rings that are connected
through a bridging atom, which can be a carbon or a sulfur, as for BPA and bisphenol
S (BPS; bis(4-hydroxyphenyl)sulfone), respectively [47]. BPA is the best known
bisphenol as it is used as a monomer in the production of polycarbonate plastic and
epoxy resins, and it is also known to be an endocrine disruptor [16, 48–54]. Both the
metabolism and endocrine effects of BPA have been studied in detail, although there
remains a lack of information on some of its analogs.
For the bisphenols, their metabolism has a protecting role. Their conjugation
with glucuronic acid and sulfate is the main in vivo transformation for all of the
bisphenols. In contrast to BPA as an agonist for the ERs, BPA glucuronide is without
estrogenic activity [55]. Similar situations have been defined for the other bisphenol
glucuronides, such as BPS glucuronide [56] and BPAF glucuronide [11]. A lack of
estrogenic activity has also been shown for BPA sulfate [57]. In contrast to these
conjugates, which are the main metabolites of the bisphenols, numerous oxidative
metabolites of BPA have been detected. However, these were mainly reported for
in vitro studies, whereas in vivo only hydroxylated BPA has been detected in feces in
mice [58] and rats [59]. The estrogenic activity of the main BPA oxidative metabo-
lite is lower than that of BPA [60]. Among the oxidative metabolites, two have
shown significantly greater estrogenic activities than BPA: its ipso metabolite 4-
methyl-2,4-bis(p-hydroxyphenyl)pent-1-ene (MBP) and hydroxycumyl alcohol.
The MBP estrogenic activity has been determined in several in vitro and in vivo
assays, in which it has shown up to 500-fold estrogenic activity over BPA (Figure 5,
Table 1) [16, 62–65]. Additionally, hydroxycumyl alcohol has shown 100-fold
estrogenic activity over BPA [66]. However, there are questions about the in vivo
relevance of these data. Indeed, although MBP has very high estrogenic activity, it
has not been detected in vivo, as BPA glucuronidation is a much faster metabolic
reaction in vivo.
Figure 5.
BPA metabolic activation through formation of the potent estrogenic metabolite MBP [61].
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Hashimoto and coworkers evaluated the estrogenic activity of 13 BPA-related
compounds using a yeast two-hybrid system without and with the addition of an S9
fraction [67]. Most of these chemicals showed enhanced estrogenic activities when
the S9 fraction was added. This might be explained by the formation of oxidative
metabolites with enhanced estrogenic activities [61]. A similar situation was
reported for bisphenol B (BPB; 2,2-bis(4-hydroxyphenyl)butane), which is a more
potent ER agonist than BPA [60]. Metabolism can also affect this BPB estrogenic
activity. Here, after incubation of BPB with an S9 fraction, there was enhanced
estrogenicity, which was probably due to the formation of BPB dimers [62, 68].
Nevertheless, in vivo, glucuronidation is the predominant metabolic pathway for the
bisphenols, while their oxidative metabolites are in most cases detected only in vitro.
5. Testing strategies
In vitro systems for evaluation of estrogenic activity are usually limited to target
chemicals, without taking into account that many chemicals are extensively metabo-
lized, which can have significant effects on their estrogenic activities. For some of the
cell lines used for endocrine testing, metabolic activities have been confirmed. How-
ever, for reliable data, it is important that the metabolic capacity of any in vitro
system is in good agreement with the in vivo conditions, although that can be
difficult to ascertain. Bursztyka and coworkers [69] evaluated the metabolic capaci-
ties toward the known endocrine disruptors genistein and BPA for various cell lines
that are commonly used in endocrine testing (i.e., the HepG2, MCF7, and HC11 cell
lines) [69]. Phase I metabolic activities were not seen for these tested cell lines. The
HepG2 and MCF7 cell lines showed glucuronidation and sulfation activities toward
genistein and BPA, while the HC11 cell line was without metabolic activity. However,
phase II metabolism in these cell lines was not representative of in vivo conditions. So,
while sulfate conjugates of genistein and BPA were the main metabolites detected in
these cell lines, it is known that genistein and BPA are mainly metabolized to glucu-
ronide conjugates in vivo [69].
Testing strategies that include metabolic aspects have not been well defined.
While different approaches can be used, they generally have many drawbacks.
Jacobsen et al. [70] used two approaches: a compound-by-compound approach and
an effects-based approach (Figure 6) [70].
Table 1.
Estrogenic agonistic activity of MBP compared to BPA, according to various in vitro and in vivo assays [61].
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In the compound-by-compound approach, the relevant metabolites are identi-
fied, isolated or synthesized, and then evaluated for their endocrine activities,
together with the parent chemical. Moreover, mixtures of a parent chemical and its
metabolites can be tested, to determine the effects of such mixtures (e.g., synergism,
additive, and antagonistic). This approach is commonly used [16, 56, 63, 71]. A
drawback to this approach is that there is a need to conduct metabolic studies, as in
many cases the metabolites are not known. Additionally, in vitro studies of metabo-
lism can result in a “pallet” of metabolites, where not all will be relevant in vivo [61].
In the effects approach, the endocrine activity of the parent chemical is com-
pared to the endocrine activity of the parent chemical treated with a metabolizing
system, which is usually an S9 fraction [70]. Incorporation of such metabolic sys-
tems into in vitro assays is a common practice when testing for genotoxicity, like for
the Ames test, where the S9 fraction is added as a source of metabolic enzymes,
although such metabolic systems are still rarely used for the evaluation of endocrine
activities of different chemicals [72].
In a recent study, a rat S9 fraction was incorporated in a CALUX reporter gene
assay (i.e., the U2-OS cell line), and 27 chemicals were evaluated [73]. Selective
inclusion of cofactors enables the evaluation of the different phases of metabolism
on the estrogenic activities (i.e., phase I, nicotinamide adenine dinucleotide phos-
phate [reduced]; phases I and II, nicotinamide adenine dinucleotide phosphate
[reduced], UDP-glucuronic acid, phosphoadenosylphosphosulfate, glutathione).
These data showed that the endocrine activities for 23 of the 27 chemicals tested
Figure 6.
Testing strategies that include metabolic aspects. The compound-by-compound approach (a) and the effects
approach (b), as proposed by Jacobsen and coworkers [70].
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were affected by metabolism. Phase II metabolism resulted in decreased estrogenic
activities, which is expected and is in agreement with in vivo data. For example,
BPA and genistein showed lower estrogenic activities after phase II metabolism. In
contrast, after phase I metabolism, 5 of the chemicals showed lower estrogenic
activities, and 11 of the chemicals showed higher estrogenic activities [73].
However, also the effects approach has many weaknesses, as, for example, the
metabolites formed in vitro are not necessarily formed in vivo. These data should
therefore be interpreted with caution. The optimal path might therefore be the
inclusion of both strategies (i.e., chemical by chemical, effects approach) [70].
Moreover, Jacobsen and coworkers proposed a five-step scheme for the evaluation
of the endocrine effects of chemicals and their metabolites [70]:
1. The endocrine activity of the parent chemical should be determined. Then,
based on all of the available information, an in vitro metabolizing system for
the production of the metabolites should be selected (e.g., S9 fractions,
microsomes, as the most common systems).
2. The compatibility of the metabolizing system and the test system for
determination of the endocrine activities should then be evaluated.
3. The mixture of metabolites formed with the metabolizing system should then
be evaluated for endocrine activity.
4.The influence of the metabolite mixture on the endocrine activity of the parent
chemical should then be evaluated.
5. The endocrine activities of the pure metabolites and their mixtures should then
be evaluated.
6. Conclusions
Metabolism is considered as a detoxification system that lowers biological activ-
ities and facilitates excretion of foreign chemicals. This appears to be true for many
estrogenic chemicals, including E2, which is metabolized to numerous metabolites
that have significantly lower estrogenic activities. However, some chemicals that
are without estrogenic activity can be metabolized to potent estrogens. Some meta-
bolic pathways in particular, such as hydroxylation on the para position of the
aromatic ring, are dangerous in terms of the metabolic activation of proestrogens.
Metabolic aspects should therefore be considered when testing chemicals for estro-
genic activities.
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